← 治験一覧に戻る
肝細胞癌患者の治療に使用されるカボザンチニブ錠の調査
基本情報
- NCT ID
- NCT05100082
- ステータス
- 完了
- 試験のフェーズ
- -
- 試験タイプ
- 観察
- 目標被験者数
- 263
- 治験依頼者名
- Takeda
概要
This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.
対象疾患
Hepatocellular Cancer
介入
Cabozantinib(DRUG)
依頼者(Sponsor)
武田薬品工業株式会社(INDUSTRY)